Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial
Authors:
- on behalf of the EPIC-NSW study groupOGon behalf of the EPIC-NSW study group
- Iryna B. ZablotskaIZIryna B. Zablotska
- Christine SelveyCSChristine Selvey
- Rebecca GuyRGRebecca Guy
- Karen PriceKPKaren Price
- Jo HoldenJHJo Holden
- Heather-Marie SchmidtHSHeather-Marie Schmidt
- Anna McNultyAMAnna McNulty
- David SmithDSDavid Smith
- Fengyi JinFJFengyi Jin
- Janaki AminJAJanaki Amin
- David A. CooperDCDavid A. Cooper
Open Access
- 2 February 2018
- journal article
- research article
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 210
Abstract
The New South Wales (NSW) HIV Strategy 2016–2020 aims for the virtual elimination of HIV transmission in NSW, Australia, by 2020. Despite high and increasing levels of HIV testing and treatment since 2012, the annual number of HIV diagnoses in NSW has remained generally unchanged. Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV infection among gay and bisexual men (GBM) when taken appropriately. However, there have been no population-level studies that evaluate the impact of rapid PrEP scale-up in high-risk GBM. Expanded PrEP Implementation in Communities in NSW (EPIC-NSW) is a population-level evaluation of the rapid, targeted roll-out of PrEP to high-risk individuals. EPIC-NSW, is an open-label, single-arm, multi-centre prospective observational study of PrEP implementation and impact. Over 20 public and private clinics across urban and regional areas in NSW have participated in the rapid roll-out of PrEP, supported by strong community mobilization and PrEP promotion. The study began on 1 March 2016, aiming to enroll at least 3700 HIV negative people at high risk of HIV. This estimate took into consideration criteria for PrEP prescription in people at high risk for acquiring HIV as defined in the NSW PrEP guidelines. Study participants receive once daily co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and are followed for up to 24 months. Follow-up includes: testing for HIV at 1 month, HIV and other sexually transmissible infections three-monthly, HCV annually and monitoring of renal function six-monthly. Optional online behavioural surveys are conducted quarterly. The co-primary endpoints are (i) HIV diagnoses and incidence in the cohort and (ii) HIV diagnoses in NSW. EPIC-NSW is a population-based PrEP implementation trial which targets the entire estimated population of GBM at high risk for HIV infection in NSW. It will provide a unique opportunity to evaluate the population impact of PrEP on a concentrated HIV epidemic. https://clinicaltrials.gov/ (identifying number NCT02870790 ; registration date 14 August 2016), pre-results stage.Keywords
Funding Information
- Department of Health, New South Wales Government
This publication has 21 references indexed in Scilit:
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- Medication Adherence Among Men Who Have Sex with Men at Risk for HIV Infection in the United States: Implications for Pre-Exposure Prophylaxis ImplementationAIDS Patient Care and STDs, 2014
- Homosexual experience and recent homosexual encounters: the Second Australian Study of Health and RelationshipsSexual Health, 2014
- The Informal Use of Antiretrovirals for Preexposure Prophylaxis of HIV Infection Among Gay Men in AustraliaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual menSexually Transmitted Infections, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Behavioural surveillance among gay men in Australia: methods, findings and policy implications for the prevention of HIV and other sexually transmissible infectionsSexual Health, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual menAIDS, 2009
- The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital TractJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008